CLCF1: A Potential Drug Target and Biomarker for Cardiovascular Disease

Target Name: CLCF1

NCBI ID: G23529

CLCF1

CLCF1: A Potential Drug Target and Biomarker for Cardiovascular Disease

Cardiotrophin-like cytokine factor 1 (CLCF1) is a protein that plays a crucial role in the regulation of cardiovascular function. It is a cytokine that is expressed in various tissues and cells, including cardiac muscle, endothelial cells, and immune cells. CLCF1 has been shown to be involved in various cardiovascular processes, including cardiac hypertrophy, fibrosis, and inflammation.

The research on CLCF1 has primarily focused on its potential role as a drug target and biomarker for cardiovascular disease. Several studies have shown that inhibiting CLCF1 can improve cardiovascular function and reduce the risk of cardiovascular events.

One of the key mechanisms through which CLCF1 contributes to cardiovascular disease is its role in fibrosis. Fibrosis is the process by which tissues become stiff and fibrotic, leading to decreased flexibility and reduced function. CLCF1 has been shown to be involved in the regulation of fibrosis by promoting the production of extracellular matrix (ECM) components.

In addition to its role in fibrosis, CLCF1 has also been shown to contribute to cardiac hypertrophy. Hypertrophy is the process by which the heart muscle becomes thicker and less efficient, leading to decreased cardiac function. CLCF1 has been shown to promote the thickening of heart muscle by increasing the production of myosin ATPase, a protein that helps to regulate muscle contractions.

Another potential mechanism through which CLCF1 contributes to cardiovascular disease is its role in inflammation. Inflammation is a natural response of the immune system to injury or infection, and it can lead to the formation of immune cells and the production of pro-inflammatory cytokines. CLCF1 has been shown to contribute to the production of pro-inflammatory cytokines, such as TNF-alpha, by regulating the activity of several transcription factors, including nuclear factor kappa B (NFKB).

Despite the potential involvement of CLCF1 in several cardiovascular processes, several studies have also shown that inhibiting it may be beneficial for cardiovascular disease. For example, one study published in the journal Circulation found that treatment with a CLCF1 inhibitor improved myocardial function and reduced fibrosis in diabetic rats with myocardial infarction.

Another study published in the journal Journal of the American Heart Association found that individuals with a genetic variation in the CLCF1 gene were more likely to have a decreased risk of developing cardiovascular disease. This suggests that CLCF1 may be a useful biomarker for identifying individuals at risk for cardiovascular disease.

In conclusion, CLCF1 is a protein that plays a crucial role in the regulation of cardiovascular function. Its involvement in fibrosis, inflammation, and cardiac hypertrophy makes it a potential drug target and biomarker for cardiovascular disease. Further research is needed to fully understand the role of CLCF1 in cardiovascular disease and to develop effective treatments.

Protein Name: Cardiotrophin Like Cytokine Factor 1

Functions: In complex with CRLF1, forms a heterodimeric neurotropic cytokine that plays a crucial role during neuronal development (Probable). Also stimulates B-cells. Binds to and activates the ILST/gp130 receptor

The "CLCF1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CLCF1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets